The recent study revealed that upregulation of EphA2 by HDAC2 and HDAC4 plays a crucial role in breast cancer, and HDACs-EphA2 signaling axis is a promising therapeutic target for advanced breast cancer32. This evidence concerns the gene EPHA2 and breast carcinoma.